Rickets Treatment Market is Segmented By Type (Vitamin D-Related Rickets, Hypophosphatemia-Related Rickets, Hypocalcemia-Related Rickets, Others), By Causes (Sunlight, Genetics, Diets, Others), By Therapy (Diagnosis, Treatment, Diet), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Rickets Treatment Market Overview
Rickets Treatment Market is estimated to reach at a high CAGR 8.4% during the forecast period (2023-2030). Rickets is a condition in which children's bones soften and deteriorate due to a severe and long-term vitamin D deficit. Genetic disorders can also cause rickets. Treatment includes exposure to sunlight, a diet rich in vitamin D and calcium, supplements, medication, or surgery.
Rickets Treatment Market Summary and Scope
|
Metrics |
Details |
|
Market CAGR |
8.4% |
|
Segments Covered |
By Type, By Causes, By Therapy, By End-User, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click Here
Rickets Treatment Market Dynamics and Trends
Conventional treatments for X-linked hypophosphatemia and FDA approvals are expected to drive market growth.
Pharmacological and non-pharmacological pain and joint stiffness therapy and adequate rehabilitation are required for the best care of symptomatic patients. Individualized exercises and tailored physical activity are recommended to increase physical function and lessen the metabolic effects of XLHR. Moreover, the FDA approved Burosumab (Crysvita), an antibody manufactured by Ultragenyx Pharmaceutical Inc. that inhibits FGF23 activity, to treat adults and children ages 1 year and older with X-linked hypophosphatemia. For children, burosumab is given by subcutaneous injection every 2 weeks, whereas adults are dosed every 4 weeks. Additionally, awareness of hypophosphatemic rickets has increased in the past years based on the availability of specific medical treatments. Thus, the market is expected to drive in the forecast period from the above statements.
COVID-19 Impact Analysis on Rickets Treatment Market
The COVID-19 pandemic has moderately impacted healthcare systems and the market. Vitamin D is a hormone that regulates the immune system and is important in microbial infection responses. It influences the transcription of immune-response genes in macrophages, T cells, and dendritic cells, affecting inflammatory processes. Vitamin D's significance in numerous infectious disorders of the respiratory tract has been established, suggesting that it may play a role in SARS-CoV-2 infection. By transforming the pro-inflammatory Th1 and Th17 responses to the anti-inflammatory Th2 and Treg response, vitamin D reduces cytokine storm. As a result, vitamin D may play a role in preventing, alleviating, or treating SARS-CoV-2 infection symptoms, such as severe pneumonia. Vitamin D may reduce the likelihood of COVID-19 infection by various mechanisms, including stimulation of cathelicidin and defensin transcription.
Additionally, the pandemic restrictions also impact vitamin D uptake by limiting exposure to sunlight, interrupting the supply chain. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market.
Rickets Treatment Market Segmentation Analysis
Hypophosphatemia-Related Rickets segment is expected to hold the largest market share in rickets treatment market
The hypophosphatemia-related rickets segment is expected to dominate in 2021. The segment benefits because Hypophosphatemic rickets is marked by low serum phosphate levels and resistance to therapy with UV light or vitamin D supplementation. Moreover, the name X-linked hypophosphatemic rickets has gained popularity as researchers have better knowledge of the genetic basis of familial hypophosphatemic rickets. The dominant condition, X-linked hypophosphatemia (XLH), accounts for more than 80% of all familial hypophosphatemia. XLH is a systemic illness caused by a mutation in the phosphate-regulating gene on the X chromosome that is similar to endopeptidases (PHEX). Therefore, it has increased the demand for the treatment of the disorders, due to which the market segment is expected to hold the largest market share in the forecast period.
Rickets Treatment Market Geographical Share
North America region holds the largest market share in the global rickets treatment market
In 2021, North America accounted for the highest revenue share. The increasing geriatric population, increasing prevalence of smoking population, increasing awareness about the diseases, well-developed healthcare, and novel treatments for the region are some factors the market is expected to boost in the forecast period. For instance, according to the Centers for Disease Control and Prevention, Nearly 40 million individuals in the United States still smoke cigarettes, and 2.55 million middle and high school kids, including e-cigarette users, use at least one tobacco product. Over 1,600 young people in the United States under 18 light up their first cigarette every day. Nearly half a million Americans die prematurely due to smoking or secondhand smoke exposure. Another 16 million people suffer from serious ailments due to smoking. The United States spends more than $225 billion per year on medical care for adults with smoking-related diseases.
Moreover, In 2020, 12.5% of U.S. adults (an estimated 30.8 million people) currently smoked cigarettes: 14.1% of men and 11% of women. Additionally, in various research studies, smoking has been recognized as a risk factor for osteoporosis and bone fracture. Therefore, it has increased the demand for the treatment of rickets in the region. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Rickets Treatment Companies and Competitive Landscape
Major key players in the rickets treatment market are Roche Laboratories Inc., Abbott Laboratories, Aphena Pharma Solutions, Teva Pharmaceuticals USA, Inc., Pharmanovia, Fermenta Biotech Limited, sanofi-aventis U.S. LLC and Profess Health Products Pvt. Ltd.
Abbott Laboratories:
Overview:
Abbott Laboratories (Abbott) develops, manufactures, and markets diagnostic devices, diabetes care, vision technologies, vascular products, and nutrition and animal health products. The company provides innovative medical devices to fulfill unmet healthcare needs. The company provides drug testing products and solutions through its diagnostics segment. Abbott Vascular, a global leader in the Cervical Cancer Diagnostics medical device industry, provides innovative, minimally invasive and cost-effective products to treat coronary artery disease. The company offers an extensive portfolio of drug-eluting stents, bare-metal stents, coronary guide wires, balloon dilatation catheters, and guiding catheters and accessories. Abbott Laboratories operates its business in over 150 countries worldwide.
Product Portfolio:
Calcijex (Calcitriol Injection): Calcijex (calcitriol injection) is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.
